Your browser doesn't support javascript.
loading
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner, Neil E; Sayyid, Rashid K; Hansen, Aaron R; Chin, Joseph L K; Fernandes, Ricardo; Winquist, Eric; van der Kwast, Theodorus; Sweet, Joan; Lajkosz, Katherine; Kenk, Miran; Hersey, Karen; Veloso, Rosette; Berlin, Doron; Herrera-Caceres, Jaime O; Sridhar, Srikala; Moussa, Madeleine; Finelli, Antonio; Hamilton, Robert J; Kulkarni, Girish S; Zlotta, Alexandre R; Joshua, Anthony M.
Affiliation
  • Fleshner NE; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Sayyid RK; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Chin JLK; Department of Surgery, Division of Urology, Western University, London, Ontario, Canada.
  • Fernandes R; Department of Oncology, Division of Medical Oncology, Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, Ontario, Canada.
  • Winquist E; Department of Oncology, Division of Medical Oncology, Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, Ontario, Canada.
  • van der Kwast T; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Sweet J; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Lajkosz K; Department of Biostatistics, University of Toronto, Toronto, Ontario, Canada.
  • Kenk M; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hersey K; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Veloso R; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Berlin D; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Herrera-Caceres JO; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Sridhar S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Moussa M; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Finelli A; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hamilton RJ; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Kulkarni GS; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Zlotta AR; Department of Surgery, Urology, Sinai Health System, Toronto, Ontario, Canada.
  • Joshua AM; Kinghorn Cancer Centre, St Vincent's Hospital, Garvan Institute of Medical Research, Sydney, Australia.
Clin Cancer Res ; 29(19): 3867-3874, 2023 10 02.
Article in En | MEDLINE | ID: mdl-37439809
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Leuprolide Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Canada Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Leuprolide Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Canada Country of publication: United States